OTCMKTS:MYCOF

Mydecine Innovations Group Stock Forecast, Price & News

$0.28
+0.03 (+11.95 %)
(As of 09/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.26
▼
$0.29
50-Day Range
$0.25
▼
$0.47
52-Week Range
$0.13
▼
$0.54
Volume481,477 shs
Average Volume1.13 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MYCOF News and Ratings via Email

Sign-up to receive the latest news and ratings for Mydecine Innovations Group and its competitors with MarketBeat's FREE daily newsletter.


Mydecine Innovations Group logo

About Mydecine Innovations Group

Mydecine Innovations Group, Inc. operates as a life sciences company dedicated to the development and commercialization of adaptive pathway medicines, natural health products and digital health solutions. It encompasses three companies: Mindleap Health, Mydecine Health Sciences, and NeuroPharm Inc. The Mindleap Health is an advanced digital health platform that helps people connect with mental health specialists who can empower them to thrive and develop habits for a healthy mind. The Mydecine Health Sciences is a vertically integrated company developing novel fungtional mushroom products and psychedelic medicines for healthy and vulnerable populations. The NeuroPharm is developing a unique and proprietary set of pharmaceutical and natural health products addressing mental wellness in vulnerable populations. The company was founded by Parente Carman on September 27, 2013 and is headquartered in Vancouver, Canada.

Headlines

Mydecine Innovations Group Inc. (OTCMKTS:MYCOF) Short Interest Down 97.5% in August
Mydecine Innovations Group Inc. (OTCMKTS:MYCOF) Short Interest Down 97.5% in August
September 14, 2021 |  americanbankingnews.com
Mydecine Innovations Group outlines plan for MYCO-001 Phase 2/3 Smoking Cessation clinical trial
Mydecine Innovations Group outlines plan for MYCO-001 Phase 2/3 Smoking Cessation clinical trial
September 10, 2021 |  proactiveinvestors.com
Mydecine Innovations Group Announces MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial
Mydecine Innovations Group Announces MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial
September 7, 2021 |  finance.yahoo.com
PharmaDrug Strikes Deal With Johns Hopkins University For A Clinical Trial Into Psychedelic DMT
PharmaDrug Strikes Deal With Johns Hopkins University For A Clinical Trial Into Psychedelic DMT
August 27, 2021 |  benzinga.com
Mydecine Innovations Group Inc. (OTCMKTS:MYCOF) Short Interest Update
Mydecine Innovations Group Inc. (OTCMKTS:MYCOF) Short Interest Update
August 26, 2021 |  americanbankingnews.com
Mydecine Innovations Group Announces Mailing of Management Information Circular and Provides Update on Spin-Out of U.S. Cannabis Assets
Mydecine Innovations Group Announces Mailing of Management Information Circular and Provides Update on Spin-Out of U.S. Cannabis Assets
August 24, 2021 |  finance.yahoo.com
Mydecine Innovations finishes 2Q with C$7M in cash after busy research period pinpoints four new lead drug candidates
Mydecine Innovations finishes 2Q with C$7M in cash after busy research period pinpoints four new lead drug candidates
August 19, 2021 |  proactiveinvestors.com
Mydecine Innovations Inks Deal With Johns Hopkins University To Undertake Psychedelics Research Into Smoking Cessation
Mydecine Innovations Inks Deal With Johns Hopkins University To Undertake Psychedelics Research Into Smoking Cessation
August 18, 2021 |  benzinga.com
Mydecine Innovations strikes five-year research agreement with John Hopkins University to study psychedelic therapies
Mydecine Innovations strikes five-year research agreement with John Hopkins University to study psychedelic therapies
August 18, 2021 |  proactiveinvestors.com
Mydecine Innovations Group signs five-year Master Collaboration Research Agreement with Johns Hopkins University School of Medicine
Mydecine Innovations Group signs five-year Master Collaboration Research Agreement with Johns Hopkins University School of Medicine
August 18, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank™

Overall MarketRank™

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Mydecine Innovations Group (OTCMKTS:MYCOF) Frequently Asked Questions

What stocks does MarketBeat like better than Mydecine Innovations Group?

Wall Street analysts have given Mydecine Innovations Group a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Mydecine Innovations Group wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Mydecine Innovations Group?

Mydecine Innovations Group saw a decline in short interest in August. As of August 31st, there was short interest totaling 4,000 shares, a decline of 97.5% from the August 15th total of 162,800 shares. Based on an average daily volume of 1,524,400 shares, the short-interest ratio is presently 0.0 days.
View Mydecine Innovations Group's Short Interest.

Who are Mydecine Innovations Group's key executives?

Mydecine Innovations Group's management team includes the following people:
  • David Joshua Bartch, Chairman, President & Chief Executive Officer
  • Damon Michaels, Chief Operating Officer & Director
  • Dean Ditto, Chief Financial Officer
  • Robert Roscow, Director & Chief Science Officer
  • Rakesh Jetly, Chief Medical Officer

Who are some of Mydecine Innovations Group's key competitors?

Some companies that are related to Mydecine Innovations Group include 1933 Industries (TGIFF), 4Front Ventures (FFNTF), AB Science (ABSCF), Abattis Bioceuticals (ATT), Acreage (ACRHF), Acreage (ACRDF), AFT Pharmaceuticals (AFP), Agraflora Organics International (AGRA), AgraFlora Organics International (AGFAF), Aleafia Health (ALEAF), American Green (ERBB), Ascend Wellness (AWWH), Australian Primary Hemp (APH), Ayr Wellness (AYRWF) and BellRock Brands (DXBRF).
View all of MYCOF's competitors.

What is Mydecine Innovations Group's stock symbol?

Mydecine Innovations Group trades on the OTCMKTS under the ticker symbol "MYCOF."

How do I buy shares of Mydecine Innovations Group?

Shares of MYCOF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mydecine Innovations Group's stock price today?

One share of MYCOF stock can currently be purchased for approximately $0.28.

What is Mydecine Innovations Group's official website?

The official website for Mydecine Innovations Group is www.mydecine.com.

Where are Mydecine Innovations Group's headquarters?

Mydecine Innovations Group is headquartered at 789 West Pender Street, Vancouver, BC V6C.

How can I contact Mydecine Innovations Group?

Mydecine Innovations Group's mailing address is 789 West Pender Street, Vancouver, BC V6C. The company can be reached via phone at (813) 871-3936.


This page was last updated on 9/16/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.